Revenue

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Integrated Biologics Revenue	3.65B	2.88B
Integrated Biologics Revenue Growth	26.57%	-22.48%
Advanced Synthesis Revenue	1.61B	1.32B
Advanced Synthesis Revenue Growth	21.77%	46.84%
Specialized Modalities Revenue	1.03B	1.10B
Specialized Modalities Revenue Growth	-5.91%	57.90%
Corporate Revenue	237.00M	175.00M
Corporate Revenue Growth	35.43%	-27.08%
Revenue (Other)	-	1.09B
Revenue (Total)	-	6.57B
Revenue (Total) Growth	-	-2.13%

Revenue by Geography

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Europe Revenue	3.14B
Europe Revenue Growth	-4.50%
North and Central America Revenue	2.44B
North and Central America Revenue Growth	8.14%
Latin America Revenue	129.00M
Latin America Revenue Growth	32.99%
Asia Revenue	837.00M
Asia Revenue Growth	-20.29%
Australia & New Zealand Revenue	17.00M
Australia & New Zealand Revenue Growth	6.25%
Other Geographic Revenue	3.00M
Other Geographic Revenue Growth	50.00%
Revenue (Total)	6.57B
Revenue (Total) Growth	-2.13%

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Integrated Biologics Core EBITDA	1.29B	1.05B
Integrated Biologics Core EBITDA Growth	23.16%	-20.59%
Advanced Synthesis Core EBITDA	674.00M	484.00M
Advanced Synthesis Core EBITDA Growth	39.26%	66.32%
Specialized Modalities Core EBITDA	176.00M	192.00M
Specialized Modalities Core EBITDA Growth	-8.33%	182.35%
Corporate Core EBITDA	-73.00M	-68.00M
Operating Income (Other)	-	-689.00M
Operating Income (Total)	-	964.00M
Operating Income (Total) Growth	-	9.54%

Updated Dec 31, 2025. Data Source: Fiscal.ai.